Literature DB >> 11121326

A challenging treatment for an ischaemic ulcer in a patient with Buerger's disease: vascular reconstruction and local flap coverage.

H Chang1, T Hasegawa, K Moteki, K Ishitobi.   

Abstract

An ischaemic heel ulcer in a patient with Buerger's disease was reconstructed using an in situ saphenous vein graft combined with a local flap. The bypass was sufficient to restore blood supply to the ischaemic limb but a flap was necessary to cover the persistent heel ulcer, which remained after revascularisation. One month after bypass surgery the ulcer was debrided and the resulting defect was covered with a lateral supramalleolar flap. The postoperative course was uneventful and the flap donor site healed well. When treating ischaemic ulcers in a patient with Buerger's disease, vascular reconstruction should be considered first in order to salvage the limb. After revascularisation, a local flap can be used to cover a persistent defect but very few local flaps have been reported. This report is the first published case of successful local flap transfer after bypass surgery in a patient with Buerger's disease. We think that a local flap is one possible treatment for a non-healing ulcer after revascularisation. Copyright 2001 The British Association of Plastic Surgeons.

Entities:  

Mesh:

Year:  2001        PMID: 11121326     DOI: 10.1054/bjps.2000.3482

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  2 in total

1.  Lateral supramalleolar flap: Is it based on perforator of peroneal / anterior tibial artery; A cross-sectional study at tertiary care centre.

Authors:  Pervaiz Mehmood Hashmi; Kamran Ahmed; Muhammad Ali; Abeer Musaddiq; Alizah Hashmi; Zohaib Nawaz
Journal:  Ann Med Surg (Lond)       Date:  2021-10-22

2.  Outcomes of endovascular treatment versus bypass surgery for critical limb ischemia in patients with thromboangiitis obliterans.

Authors:  Chung Yeop Lee; Kyunghak Choi; Hyunwook Kwon; Gi-Young Ko; Youngjin Han; Tae-Won Kwon; Yong-Pil Cho
Journal:  PLoS One       Date:  2018-10-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.